Research into VCAM-1 mAbs as novel anti-inflammatory agents has been conducted in several immunological disease models involving VCAM-1 overexpression, such as asthma49,166,167 and colitis.50,168,169 While the role of VCAM-1 has been well-characterized in atherosclerosis, studies into the anti-atherosclerotic potential of VCAM-1 mAbs remain extremely limited. This evidence concerns the gene VCAM1 and atherosclerosis.